Repositioning Candidate Details
| Candidate ID: | R0227 |
| Source ID: | DB00806 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Pentoxifylline |
| Synonyms: | |
| Molecular Formula: | C13H18N4O3 |
| SMILES: | CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C |
| Structure: |
|
| DrugBank Description: | A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem] |
| CAS Number: | 6493-05-6 |
| Molecular Weight: | 278.307 |
| DrugBank Indication: | For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs. |
| DrugBank Pharmacology: | Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| DrugBank MoA: | Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist. |
| Targets: | Adenosine receptor A2a; NA; Adenosine receptor A1; 5'-nucleotidase |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|